The FDA in July 2025 made publicly available over 200 complete response letters—an initiative that the investment community ...
Innate Pharma S.A. is a global, clinical-stage biotechnology company developing immunotherapies for cancer patients. Leveraging its expertise on antibody-engineering and innovative target ...
Medicus Pharma CEO Dr Raza Bokhari joined Steve Darling from Proactive to announce that the company has submitted an Orphan ...
Daily Voice Prince George's County MD on MSN
Purdue Pharma Files New $7.4B Bankruptcy Plan: How Opioid Victims, Families Could Benefit
Purdue Pharma has filed a new bankruptcy plan that will distribute more than $7.4 billion to compensate opioid epidemic ...
Silo Pharma, Inc. announced the filing of a provisional patent application for its lead asset, SPC-15, aimed at treating stress-induced psychiatric disorders such as PTSD. The patent focuses on the ...
The buyback will open on 23 April and close on 29 April 2026, with the last date for submission of tender forms and related ...
the annual financial report, the annual management report, the corporate governance report provided for under Article L. 225-37 of the French Commercial Code, the report of Statutory Auditors. Innate ...
Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“Innate” or the “Company”) today announced the filing of its 2025 Universal Registration Document (Document d’enregistrement universel) for the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results